David R Wise

8PUBLICATIONS
70CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer geneticsGenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 26, 2026
Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors.

|Sep 22, 2025
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.

Neal D Shore, Christopher M Pieczonka, Sean Heron

|Mar 13, 2025
Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future.

Matthew Siskin, Minas P Economides, David R Wise

|Dec 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.

Neal Shore, Sarah M Nielsen, Edward D Esplin

|Mar 07, 2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.

Stacy Loeb, Scott W Keith, Heather H Cheng

|Feb 10, 2024
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

David R Wise, Russell K Pachynski, Samuel R Denmeade

Pageof 2

Frequent Collaborators

2 joint publications

Matthew Siskin

2 joint publications

Victor Adorno Febles

2 joint publications

Edward D Esplin

2 joint publications

Neal Shore